La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 17th Annual BIO CEO & Investor Conference taking place February 9-10 in New York City.

17th Annual BIO CEO & Investor Conference Presentation Details

    
      
        
          Date:
        
        
           
        
        
           
        
        
          Monday, February 9, 2015
        
      
      
        
          Time:
        
        
        
        
        
        
          5:30 pm Eastern Time
        
      
      
        
          Location:
        
        
        
        
        
        
          Louis XVI Room @ The Waldorf Astoria New York
        
      
      
        
          Webcast:
        
        
        
        
        
        
          

LJPC Webcast Link

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of iron overload. For more information on La Jolla, please visit www.ljpc.com.

La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D., Ph.D.President & Chief Executive Officer(858) [e-mail] S. Zygmont, IIISenior Director of Finance(858) [e-mail]